Head and Neck Cancer Study Project in the Geriatric Population (NCT06998069)
🩺 Plain-English Summary (8th-Grade Level)
This is a study conducted in patients with a diagnosis of stage IB-IVA squamous cell carcinoma of the head and neck. Patients will have a comprehensive geriatric assessment (CGA) as part of standard assessments. The patients classified as frail, with a CGA score of 3-5, will then be treated with a novel reduced intensity regimen. The regimen will be tailored based on the programmed cell death ligand 1 combined positive score (PD-L1 CPS) and will involve 4 cycles of systemic chemotherapy and/or immunotherapy followed by radiation treatment.
Who can join: Review the eligibility criteria below.
Location: Rhode Island and The Miriam Hospitals — Providence, Rhode Island
Age range: 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Rhode Island and The Miriam Hospitals — Providence, Rhode Island
📞 Contact the Study Coordinator
Phone: (401) 863-3000
Email: BrUOG@brown.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Head and Neck Neoplasms
- Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) — La Jolla, California
- Access to Care Pilot for ED-Presenting Head and Neck Cancer Patients (ENRICH-HNC) — Orlando, Florida
- Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC — Chicago, Illinois
- Molecular and Genomic Profiling of Head and Neck Tumors — The Bronx, New York
- EMST in Patients Undergoing CRT for HNCA — Milwaukee, Wisconsin
Explore by condition: All Head and Neck Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.